Concepts (140)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Receptors, Cytoplasmic and Nuclear | 6 | 2019 | 392 | 1.150 |
Why?
|
Kupffer Cells | 2 | 2020 | 21 | 0.860 |
Why?
|
Receptors, Calcitriol | 2 | 2020 | 72 | 0.840 |
Why?
|
Hepatitis | 2 | 2020 | 65 | 0.710 |
Why?
|
Diabetes Mellitus, Experimental | 2 | 2009 | 139 | 0.620 |
Why?
|
Liver | 7 | 2020 | 1857 | 0.570 |
Why?
|
Insulin Resistance | 2 | 2020 | 631 | 0.510 |
Why?
|
Non-alcoholic Fatty Liver Disease | 1 | 2020 | 387 | 0.480 |
Why?
|
beta Catenin | 1 | 2015 | 209 | 0.440 |
Why?
|
Carcinogenesis | 1 | 2015 | 335 | 0.390 |
Why?
|
Proto-Oncogene Proteins c-akt | 3 | 2023 | 492 | 0.370 |
Why?
|
RNA Helicases | 2 | 2022 | 63 | 0.370 |
Why?
|
Prostatic Neoplasms, Castration-Resistant | 2 | 2022 | 85 | 0.360 |
Why?
|
Fatty Liver | 1 | 2009 | 181 | 0.300 |
Why?
|
Receptors, Steroid | 1 | 2009 | 269 | 0.300 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2018 | 66 | 0.280 |
Why?
|
Mammary Neoplasms, Animal | 2 | 2018 | 137 | 0.270 |
Why?
|
Mice, Inbred C57BL | 6 | 2020 | 4391 | 0.260 |
Why?
|
Mitogen-Activated Protein Kinases | 2 | 2023 | 207 | 0.250 |
Why?
|
Mice | 14 | 2024 | 17646 | 0.230 |
Why?
|
Diet, High-Protein | 1 | 2024 | 5 | 0.230 |
Why?
|
Hepatocytes | 4 | 2020 | 257 | 0.220 |
Why?
|
3-Phosphoinositide-Dependent Protein Kinases | 1 | 2023 | 18 | 0.220 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2023 | 342 | 0.220 |
Why?
|
Prostatic Neoplasms | 2 | 2022 | 1518 | 0.210 |
Why?
|
GATA2 Transcription Factor | 1 | 2022 | 45 | 0.210 |
Why?
|
Animals | 15 | 2024 | 33911 | 0.200 |
Why?
|
Receptors, Androgen | 2 | 2022 | 409 | 0.190 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2009 | 791 | 0.190 |
Why?
|
Copper-transporting ATPases | 1 | 2020 | 27 | 0.170 |
Why?
|
Phosphatidylethanolamine N-Methyltransferase | 1 | 2019 | 11 | 0.170 |
Why?
|
Macrophage Activation | 1 | 2020 | 62 | 0.170 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2022 | 351 | 0.170 |
Why?
|
Hepatolenticular Degeneration | 1 | 2020 | 36 | 0.170 |
Why?
|
Endoplasmic Reticulum Stress | 1 | 2020 | 122 | 0.160 |
Why?
|
MAP Kinase Signaling System | 1 | 2021 | 320 | 0.160 |
Why?
|
Gene Transfer Techniques | 2 | 2018 | 374 | 0.160 |
Why?
|
Disease Models, Animal | 3 | 2020 | 4308 | 0.160 |
Why?
|
Triple Negative Breast Neoplasms | 1 | 2022 | 225 | 0.160 |
Why?
|
Vitamin D | 1 | 2020 | 155 | 0.150 |
Why?
|
Alpharetrovirus | 1 | 2018 | 5 | 0.150 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2022 | 1885 | 0.150 |
Why?
|
Gene Knockout Techniques | 1 | 2018 | 128 | 0.150 |
Why?
|
Retroviridae | 1 | 2017 | 205 | 0.140 |
Why?
|
Atrial Fibrillation | 1 | 2024 | 622 | 0.140 |
Why?
|
Inflammation | 2 | 2020 | 1399 | 0.130 |
Why?
|
Bile Acids and Salts | 2 | 2009 | 237 | 0.130 |
Why?
|
Aldehydes | 1 | 2015 | 28 | 0.130 |
Why?
|
Mice, Knockout | 5 | 2020 | 3782 | 0.120 |
Why?
|
Microsomes, Liver | 1 | 2015 | 86 | 0.120 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 2015 | 59 | 0.120 |
Why?
|
Mitochondria | 1 | 2019 | 684 | 0.120 |
Why?
|
Oxidation-Reduction | 2 | 2019 | 444 | 0.120 |
Why?
|
Quinazolines | 1 | 2015 | 175 | 0.120 |
Why?
|
Cellular Senescence | 1 | 2015 | 159 | 0.110 |
Why?
|
Cell Line, Tumor | 4 | 2022 | 3299 | 0.110 |
Why?
|
o-Aminoazotoluene | 1 | 2011 | 1 | 0.100 |
Why?
|
Protein Kinase Inhibitors | 1 | 2015 | 520 | 0.090 |
Why?
|
Male | 8 | 2022 | 59687 | 0.090 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2015 | 721 | 0.090 |
Why?
|
Mice, SCID | 2 | 2022 | 572 | 0.090 |
Why?
|
Diabetic Nephropathies | 1 | 2011 | 110 | 0.090 |
Why?
|
Sulfotransferases | 1 | 2009 | 27 | 0.080 |
Why?
|
Self Care | 1 | 2011 | 205 | 0.080 |
Why?
|
Mice, Obese | 1 | 2009 | 77 | 0.080 |
Why?
|
Inactivation, Metabolic | 1 | 2009 | 33 | 0.080 |
Why?
|
Lipogenesis | 1 | 2009 | 59 | 0.080 |
Why?
|
Obesity | 1 | 2020 | 1950 | 0.080 |
Why?
|
Breast Neoplasms | 2 | 2022 | 2478 | 0.080 |
Why?
|
Glucose Tolerance Test | 1 | 2009 | 203 | 0.080 |
Why?
|
Neoplasms | 1 | 2023 | 2749 | 0.080 |
Why?
|
Gene Expression Regulation | 3 | 2020 | 2541 | 0.080 |
Why?
|
Gene Expression Profiling | 1 | 2015 | 1680 | 0.070 |
Why?
|
Patient Education as Topic | 1 | 2011 | 422 | 0.070 |
Why?
|
AMP-Activated Protein Kinases | 1 | 2009 | 166 | 0.070 |
Why?
|
Membrane Proteins | 1 | 2015 | 1529 | 0.070 |
Why?
|
Signal Transduction | 3 | 2023 | 4524 | 0.070 |
Why?
|
DNA-Binding Proteins | 2 | 2024 | 2058 | 0.070 |
Why?
|
Liver Regeneration | 1 | 2006 | 52 | 0.070 |
Why?
|
Hep G2 Cells | 2 | 2019 | 92 | 0.070 |
Why?
|
Antineoplastic Agents | 1 | 2015 | 1682 | 0.070 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2015 | 961 | 0.070 |
Why?
|
Blood Glucose | 1 | 2009 | 1095 | 0.060 |
Why?
|
Humans | 12 | 2023 | 122517 | 0.060 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2011 | 816 | 0.060 |
Why?
|
Insulin | 1 | 2009 | 1190 | 0.060 |
Why?
|
Liver Neoplasms | 1 | 2015 | 1389 | 0.060 |
Why?
|
Cytoplasm | 1 | 2024 | 290 | 0.050 |
Why?
|
Inflammasomes | 1 | 2024 | 149 | 0.050 |
Why?
|
Androgen Antagonists | 1 | 2022 | 114 | 0.050 |
Why?
|
Mutation | 1 | 2015 | 5793 | 0.050 |
Why?
|
Androgens | 1 | 2022 | 257 | 0.040 |
Why?
|
S-Adenosylmethionine | 1 | 2019 | 30 | 0.040 |
Why?
|
PTEN Phosphohydrolase | 1 | 2022 | 269 | 0.040 |
Why?
|
Unfolded Protein Response | 1 | 2020 | 62 | 0.040 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2022 | 428 | 0.040 |
Why?
|
Interleukin-1beta | 1 | 2020 | 160 | 0.040 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2022 | 880 | 0.040 |
Why?
|
HEK293 Cells | 1 | 2021 | 745 | 0.040 |
Why?
|
Interleukin-6 | 1 | 2020 | 394 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-myc | 2 | 2011 | 187 | 0.040 |
Why?
|
Metabolome | 1 | 2020 | 294 | 0.040 |
Why?
|
Oncogenes | 1 | 2018 | 172 | 0.040 |
Why?
|
Transcription Factors | 1 | 2006 | 2588 | 0.030 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2017 | 217 | 0.030 |
Why?
|
Metabolic Detoxication, Phase I | 1 | 2015 | 10 | 0.030 |
Why?
|
Imines | 1 | 2015 | 9 | 0.030 |
Why?
|
Metabolic Detoxication, Phase II | 1 | 2015 | 14 | 0.030 |
Why?
|
Cytochrome P-450 CYP3A Inhibitors | 1 | 2015 | 10 | 0.030 |
Why?
|
Glucose | 1 | 2020 | 876 | 0.030 |
Why?
|
Sequence Deletion | 1 | 2017 | 528 | 0.030 |
Why?
|
Isoenzymes | 1 | 2015 | 223 | 0.030 |
Why?
|
Molecular Structure | 1 | 2015 | 285 | 0.030 |
Why?
|
Neoplasm Metastasis | 1 | 2017 | 653 | 0.030 |
Why?
|
ErbB Receptors | 1 | 2015 | 285 | 0.030 |
Why?
|
Female | 4 | 2022 | 65064 | 0.030 |
Why?
|
RNA, Messenger | 2 | 2011 | 2833 | 0.030 |
Why?
|
Metabolomics | 1 | 2015 | 396 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2015 | 1404 | 0.020 |
Why?
|
Cytochrome P450 Family 2 | 1 | 2011 | 7 | 0.020 |
Why?
|
Steroid Hydroxylases | 1 | 2011 | 20 | 0.020 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 1 | 2011 | 43 | 0.020 |
Why?
|
Program Evaluation | 1 | 2011 | 441 | 0.020 |
Why?
|
Patient Compliance | 1 | 2011 | 456 | 0.020 |
Why?
|
Lung Neoplasms | 1 | 2017 | 1586 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2011 | 1023 | 0.020 |
Why?
|
Cholestyramine Resin | 1 | 2006 | 13 | 0.020 |
Why?
|
Forkhead Box Protein M1 | 1 | 2006 | 9 | 0.020 |
Why?
|
Cholic Acid | 1 | 2006 | 17 | 0.020 |
Why?
|
Cholesterol 7-alpha-Hydroxylase | 1 | 2006 | 36 | 0.020 |
Why?
|
Genes, myc | 1 | 2006 | 99 | 0.020 |
Why?
|
Growth Substances | 1 | 2006 | 113 | 0.020 |
Why?
|
Cell Count | 1 | 2006 | 253 | 0.020 |
Why?
|
Hepatectomy | 1 | 2006 | 121 | 0.020 |
Why?
|
DNA Replication | 1 | 2006 | 345 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2011 | 2321 | 0.010 |
Why?
|
Forkhead Transcription Factors | 1 | 2006 | 371 | 0.010 |
Why?
|
Homeostasis | 1 | 2006 | 682 | 0.010 |
Why?
|
Cytokines | 1 | 2006 | 1286 | 0.010 |
Why?
|
Diet | 1 | 2006 | 1092 | 0.010 |
Why?
|